2026-10-14T06:30:22Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33979924 2026-09-24T05:33:11Z category_393 portal_316 item_type_3 month_year_09_2026

Table 1_Clinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort study.docx Fei Yang (46361) Dongrui Peng (21192289) Chen Wang (88408) Xin Yang (104842) Lijie Wang (279386) Yaolong Chen (362838) Fang Wang (105926) Foetal Development and Medicine chronic endometritis doxycycline medroxyprogesterone acetate prospective cohort study recurrent reproductive failure Introduction<p>Chronic endometritis (CE) is associated with recurrent reproductive failure (RRF), but the optimal treatment strategy remains uncertain. This study evaluated the efficacy and safety of doxycycline plus medroxyprogesterone acetate (MPA) in women with RRF and CE.</p>Material and methods<p>This prospective cohort study included 330 women with RRF and CE diagnosed by CD138 immunohistochemistry. According to the treatment received, patients were classified into the doxycycline group or the doxycycline plus MPA group, with 165 women in each group. The primary outcome was the histological cure rate of CE after one treatment course. Secondary outcomes included pregnancy rate, live birth rate, pregnancy loss rate, ongoing pregnancy rate, and adverse events. Multivariable Poisson regression with robust variance was used to adjust for potential confounders.</p>Results<p>In the primary efficacy population, CE cure occurred in 117 of 158 patients (74.1%) receiving doxycycline and 130 of 160 (81.2%) receiving doxycycline plus MPA [adjusted risk difference [aRD], 6.1; 95% CI, −3.2–15.4; adjusted risk ratio [aRR], 1.08; 95% CI, 0.96–1.22; P = 0.202]. Pregnancy occurred in 97 of 158 patients (61.4%) and 126 of 160 (78.8%) (aRD, 16.5 percentage points; 95% CI, 6.5–26.5; aRR, 1.27; 95% CI, 1.09–1.47; P = 0.002). Adverse events occurred in 12 of 165 patients (7.3%) in each group and were all mild.</p>Conclusion<p>Doxycycline plus MPA did not significantly improve the CE cure rate in women with RRF and CE, but was associated with a higher pregnancy rate without an increase in adverse events.</p>Trial registration<p>This study was registered in the Chinese Clinical Trial Registry with the registration number of ChiCTR2400080514 (31/01/2024)</p> 2026-09-24T05:33:11Z Dataset Dataset 10.3389/fmed.2026.1913511.s001 https://figshare.com/articles/dataset/Table_1_Clinical_efficacy_and_pregnancy_outcomes_of_doxycycline_plus_medroxyprogesterone_acetate_therapy_for_chronic_endometritis_in_women_with_recurrent_reproductive_failure_a_prospective_cohort_study_docx/33979924 CC BY 4.0